newsfilter
← Latest News
GlobeNewswire·

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)